<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesJohn S. Welch, Timothy J. Ley, Allegra A. Petti et al.|New England Journal of Medicine|2016Cited by 783
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemiaZhaohui Gu, Williams E. Evans, Ashley Hill et al.|Nature Genetics|2019Cited by 616
Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor StudyEugene Suh, Tara O. Henderson, Kayla Stratton et al.|The Lancet Oncology|2020Cited by 370
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE studyHagop M. Kantarjian, Anjali S. Advani, Daniel J. DeAngelo et al.|Cancer|2019Cited by 327
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic LeukemiaStuart E. Siegel, Archie Bleyer, Wendy Stock et al.|JAMA Oncology|2018Cited by 168